crohn's disease and glp-1 Role of glucagon-like peptides in inflammatory bowel diseases—current knowledge future perspectives | Naunyn-Schmiedeberg's Archives of Pharmacology Frontiers | GLP-1 and GLP-2

The pancreatic receptors improve blood sugar control

Digital health platforms were already set up to prescribe online, ship medications directly to patients, drive patient engagement, and operate outside of traditional insurance systems

A recent study involving 3,390 people taking semaglutide or liraglutide found participants who took high doses of their drug 1.7 mg, 2.0 mg or 2.4 mg of semaglutide, or 3 mg of liraglutide lost more weight after a year compared to people taking lower doses

GLP-1 drugs have been extensively studied and are known to be effective across a wide range of patients, including those with diabetes and obesity

Failure to identify the responsible drug can lead to significant delays in treatment, potentially resulting in critical outcomes (Jones et al., 2015)